Trial Profile
Safety and efficacy of the combination treatment BRAFi +/- MEKi with anti-PD1 agents (pembrolizumab and nivolumab) in subjects with metastatic melanoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs Mitogen-activated protein kinase kinase inhibitors (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Proto oncogene protein b raf inhibitors (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology